Eiffel to focus on developing inhaled and transdermal insulin
Wednesday, 31 March, 2004
Eiffel Technologies (ASX : EIF) announced today it has completed further animal studies in its development of improved injectable insulin, and would focus resources on collaborations with pharmaceutical companies working on inhaled or transdermal insulin.
The studies confirmed that Eiffels re-engineered insulin is at least equivalent to the commercially available forms of the drug.
Eiffel has supplied re-engineered insulin to companies for use in either oral or transdermal delivery. These companies will be testing Eiffel's product in different delivery devices.
“We must prioritise our insulin research to areas where the technology has the potential to add maximal commercial and shareholder value“, said Eiffel’s Managing Director and CEO, Christine Cussen. “The potential opportunities for inhaled and oral insulin are large and we want to capitalise on these opportunities.”
'Mini brains' mimic MS myelin damage
The MS organoids give researchers a highly detailed cellular view of myelin destruction...
Fast-aging placentas may contribute to pre-eclampsia
Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...
BioNTech opens mRNA manufacturing facility at La Trobe
Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...
